Invention:
This technology seeks to take advantage of members of the FET protein family that are translocated to form fusion oncogenes. This presents an opportunity to use FET-protein fusions as a means of identifying and treating cancer. Combined treatment of Ewing's sarcoma with a transcription inhibitor, such as flavopiridol, increases cellular sensitivity to DNA damage agents. Tumors showing translocation of these FET proteins would also be susceptible to treatment with transcription inhibitors.
Background:
It is estimated that 12,390 people will be diagnosed with and 4,990 will die annually from soft-tissue-sarcoma in the United States. Because current treatment options are invasive and expensive, patients are left with negative side effects and large financial burdens. This technology helps to remedy this issue by providing a source of relief that is less invasive and burdensome.
Applications:
- Ewing’s sarcoma
- Potential to treat other cancers
Advantages:
- Non-invasive and specific means to target conditions like Ewing's sarcoma
- Indicates and sensitizes tumors for more effective treatment
- Limits treatment toxicity effects by lower dose requirements
